meta_pixel
Tapesearch Logo
Log in
The Peter Attia Drive

#267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.

The Peter Attia Drive

Peter Attia, MD

Health & Fitness, Medicine, Fitness

4.77.3K Ratings

🗓️ 21 August 2023

⏱️ 110 minutes

🧾️ Download transcript

Summary

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin.

We discuss:

  • Keith’s interest and expertise in cancer [3:15];
  • Cancer deaths by decade of life, and how cancer compares to other top causes of death [7:00];
  • The relationship between hormones and cancer [12:00];
  • The link between obesity and cancer [18:45];
  • Current state of treatments for metastatic cancer and reasons for the lack of progress over the decades [22:30];
  • The interplay between the immune system and cancer cells [32:00];
  • Different ways cancer can suppress the immune response, and how immunotherapy can combat cancer’s evasive tactics [39:30];
  • Elimination of a substantial portion of cancers through immune cell engineering faces challenges of specificity, cost, and scalability [52:15];
  • Why TIL therapy isn’t always effective, and the necessity for multimodal therapy to address various aspects of the cancer microenvironment [1:01:00];
  • Potential developments in cancer therapy over the next five years: T-cell activation, metabolic interventions, targeting tumor microenvironments, and more [1:06:30];
  • The challenge of treating metastatic cancer underscores the importance of early detection to improve survivability [1:19:15];
  • Liquid biopsies for early detection of cancer and determining the possible tissue of origin [1:24:45];
  • Commercially available cancer screening tests [1:33:45];
  • How to address the disparity in cancer care, and the exciting pace of progress for cancer detection and treatment [1:40:15]; and
  • More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Transcript

Click on a timestamp to play from that location

0:00.0

Hey everyone, welcome to the Drive Podcast. I'm your host Peter Atilla. This podcast,

0:16.6

my website, and my weekly newsletter all focus on the goal of translating the science

0:21.0

of longevity into something accessible for everyone. Our goal is to provide the best

0:25.7

content and health and wellness, and we've established a great team of analysts to make

0:29.9

this happen. It is extremely important to me to provide all of this content without

0:34.6

relying on paid ads. To do this, our work is made entirely possible by our members, and

0:39.4

in return, we offer exclusive member-only content and benefits above and beyond what is

0:45.1

available for free. If you want to take your knowledge of this space to the next level,

0:49.9

it's our goal to ensure members get back much more than the price of the subscription.

0:54.6

If you want to learn more about the benefits of our premium membership, head over to

0:58.6

peteratilla-md.com forward slash subscribe.

1:04.6

My returning guest this week is Dr. Keith Flarity. Keith was a previous guest on episode

1:09.7

number 62 of the drive way back in July of 2019. Keith is currently the director of

1:15.9

clinical research at the Massachusetts General Hospital Cancer Center and a professor

1:20.6

of medicine at Harvard Medical School, and he serves as the editor-in-chief of clinical

1:25.3

cancer research, a very prestigious journal. His research focuses on understanding novel

1:30.8

molecularly targeted therapies and cancer. Within this field, his focus has been on the

1:35.9

development of response and predictive biomarkers to define the mechanism of action and resistance

1:42.0

of novel therapies as well as to identify the optimal target populations. In this episode,

1:46.9

we start by looking at some of the statistics around the prevalence of cancer as we age.

1:51.4

This really highlights the importance of this topic, and although we don't spend a lot

1:54.5

of time on it because I think intuitively people understand that I do think it's important

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Peter Attia, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Peter Attia, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.